Key result
Vincristine therapy can cause delayed vascular toxicity, presenting as eccentric fibrotic obstruction of the superior vena cava and resulting in superior vena cava syndrome.
This case report provides the first description of vincristine-induced vascular toxicity presenting as superior vena cava fibrotic obstruction.
Answers are grounded in this paper and cite their sources.
Clinicians should consider vincristine in delayed SVC syndrome; first report leaves open incidence and monitoring needs.
We report an extremely rare case of vincristine-induced fibrotic obstruction of the upper superior vena cava (SVC) in a 42-year-old female. She recovered from non-Hodgkin's lymphoma 5 years back and presented with SVC syndrome. Our case is the first description of vascular toxicity of vincristine with SVC fibrotic obstruction.
No takes yet. Share an insight, caveat, or question.
Das et al. (2023) studied this question. Vincristine therapy can cause delayed vascular toxicity, presenting as eccentric fibrotic obstruction of the superior vena cava and resulting in superior vena cava syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: